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Abstract
This case reports the efficacy of metaflumizone plus amitraz spot-on formulation (ProMeris Duo®;
Fort Dodge) against generalized demodectic mange. A two year-old male dog presented at clinical
examination with poor general condition, diffused alopecia, crusted lesions, pruritus, skin scales and
pustules. Demodex mites, Malassezia pachydermatis yeasts and bacteria were diagnosed. The dog
was treated with cephalexin and topically with metaflumizone plus amitraz spot on formulation at
two weeks intervals until two consecutive skin scrapings resulted negative for mites. The number
of adult mites statistically decreased at follow-up with a reduction of approximately 42 and 94% at
+14 and +28 days post treatment (p.t.) respectively. Nymphs and larvae could not be detected from
+28 day p.t. while eggs were no longer present +42 day p.t. The dog was negative for both bacteria
and  M. pachydermatis at 14 days p.t., coinciding with improved general clinical conditions,
recovering skin lesions and no further signs of pruritus. These results show that metaflumizone plus
amitraz associated with the antibiotic therapy is highly effective for treating generalized demodectic
mange and could also be effective toward controlling M. pachydermatis opportunistic infections.
Findings
Demodex canis (Acari, Demodicidae), a common compo-
nent of canine skin, can cause skin disease in immune-
depressed subjects with symptoms including localized or
diffuse alopecia, erythema, comedones associated with
papular and pustular dermatitis [1]. Indeed, a high
number of Demodex spp. mites within the follicles and
sebaceous glands causes canine demodicosis [1], which is
often associated with folliculitis and furunculosis due to
secondary bacterial and/or mycotic infections [2]. Among
the latter are Malassezia spp. lipophylic yeasts that are part
of the normal cutaneous microflora of most warm-
blooded animals. These may suddenly act as opportunis-
tic pathogens causing dermatitis or otitis in dogs [3]. In
dogs, a significant proliferation of Malassezia pachyderma-
tis is likely a preliminary step toward dermatitis and/or
otitis [4,5], its overgrowth being caused by changes in the
cutaneous microenvironment and/or alterations of host
defence mechanisms [3]. Under the above circumstances
both Demodex spp. infection and Malassezia overgrowth
may be responsible for severe skin lesions in dogs [2,3].
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The clinical presentation of demodectic mange depends
on the age of the infected animals [6]. Young dogs (< 2
years old) can be affected by localized or generalized
forms of demodicosis based on the extension and locali-
zation of the lesions [1]. Indeed, the presence of more
than five localized lesions on the body, or of two or more
feet affected by parasitic lesions, are indicative of general-
ized infection [6]. In adult dogs (i.e. > 4 years of age)
demodectic mange may occur as a generalized form [6]. It
has been proposed that the critical factors for the appear-
ance of clinical signs of demodectic mange are genetic pre-
disposition (e.g. breed) and/or immunosuppressive
conditions (e.g. neoplasia, diabetes, hyperadrenocorti-
cism and metabolic disease) [1].
The diagnosis of mange is usually based on the detection
of mites in skin scrapings both in presence or absence of
lesions. Treatment is based on chemical control of the
mites and supportive therapy for opportunistic Malassezia
or bacterial infection [2]. Juvenile-onset localized demo-
dectic mange resolves without treatment in 90% of cases,
whereas in some patients the administration of topical or
oral antibiotics is needed in order to control the secondary
bacterial skin infections [6]. Conversely, generalized
demodectic mange is a serious condition requiring a pro-
longed pharmacological treatment, which is often consid-
ered difficult and potentially life-threatening [7]. Because
the life cycle of the mite extends over a period of 18–24
days [8] and due to the difficulties experienced with the
treatment of generalized demodicosis, multiple
approaches are advised.
Amitraz is the only molecule approved by the Food and
Drug Administration (FDA) for the treatment of canine
demodicosis [6]. This molecule belongs to the formami-
dine family and acts by inhibiting monoamine oxidase
and prostaglandin synthesis and by stimulating the alfa 2
– adrenergic receptors of the arthropod nervous system.
Treatment protocols vary according to the extent and
severity of lesions. Whole-body rinses to topical treatment
of localized lesions (e.g. pododemodicosis), at different
concentrations and intervals [9,10]. Several side effects
(e.g. lethargy, depression, anorexia, vomiting, diarrhoea,
hypothermia, ataxia, pruritus, bradycardia, hyperglyc-
emia) were reported in some breeds (e.g. collie) and,
more rarely, in owners handling the drug [6]. Alterna-
tively macrocyclic lactones (i.e. avermectins and milbe-
mycines) are also used as pour-on, oral or injectable
formulations to treat generalized demodicosis [7,10].
A novel amitraz (499,5 mg) plus metaflumizone (499,5
mg) association in a spot-on formulation (ProMeris Duo®;
Fort Dodge, Animal Health, Overland Park, KS) has
recently been registered for treatment of flea and tick
infections in dogs [11,12]. Metaflumizone is an insecti-
cide blocking the passage of sodium through nervous cell
membranes in arthropods, preventing the onset of nerv-
ous impulses. The association has shown good efficacy in
treating generalized canine demodectic mange with a sig-
nificant reduction of the number of adult mites and eggs
at 14 or 28 days post treatment [7]. The aim of the present
study was to describe a case report of severe generalized
demodectic mange associated to Malassezia infection and
to evaluate the efficacy and the safety of amitraz (499.5
mg) plus metaflumizone (499.5 mg) spot-on formulation
for its treatment.
In February 2008, a two year-old male mixed-breed dog,
weighing 18 kilograms, was referred by the owner to the
Parasitological Unit of the Faculty of Veterinary Medicine
of Bari (Apulia region, Southern Italy). The animal pre-
sented with poor general condition and showed lymph-
node enlargement and fever (40°C). The dog exhibited
seborrhoea on the whole body surface with extensive
areas of alopecia, crusted lesions which were more severe
on the legs, neck and face, and pruritus (Figure 1). In par-
ticular, the patient showed diffused bleeding wounds
around the eyes and serious traumatic corneal lesions.
Based on the animal's history and physical examination,
the differential diagnosis included ectoparasitic infec-
tions, leishmaniosis, neoplasia, mycobacteriosis, dermat-
ophytosis and combined anaerobic and aerobic bacterial
Patient at day 0 (before treatment) and on day +14 and +28,  post treatment Figure 1
Patient at day 0 (before treatment) and on day +14 
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infections. Anti-Leishmania antibodies were not detected
by Indirect Fluorscence Antibody Test (IFAT). The haemo-
gram revealed neutrophilic leucocytosis while the serum
chemistry panel showed no abnormal findings except for
hyperproteinemia and hyperglobulinemia.
Demodex spp. mite infestation was diagnosed by deep skin
samples collected from three anatomical sites (i.e. ante-
rior left leg, thorax and tight). Each scraping was per-
formed on a skin area of approximately 1 square cm.
Further samples were taken at day 0 (before treatment)
and on days +14, +28, +42, +56, +70 and +84 post treat-
ment (p.t., i.e. until two consecutive skin scrapings were
found negative). Samples were cleared in 10% KOH solu-
tion, for 15 minutes at room temperature, and observed
under the microscope. The number of immature stages
(larvae and nymphs), adults and eggs were counted at
each scraping and recorded separately. The animal was
also clinically evaluated by systematically recording the
extent of skin lesions and photographed at each follow-
up.
Malassezia spp. infection was diagnosed in five anatomical
sites (i.e., inguinal, interdigital, external ear canal, perio-
ral, and periorbital areas) using sterile cotton swabs mois-
tened with sterile saline (0.9% NaCl) solution [4,5].
Samples were taken at the same time-points as above. A
total of 35 swabs were collected and inoculated on modi-
fied Dixon's agar within two hours from collection and
Petri dishes were incubated at 32°C for seven days.
Because no more than 300 non-confluent colonies of
Malassezia  per plate can be clearly identified by visual
inspection, the maximum number of colonies counted
per plate was 300. The results were reported as number of
colony forming units (CFU) per swab. Four colonies from
each positive sample were sub-cultured in modified
Dixon's agar for subsequent categorization using the dif-
ferent Tween (i.e. 20, 40, 60, 80) assimilation methods as
previously described [13]. The tryptophan and cremophor
EL (PeG 35 castor oil-Sigma-Aldrich, Italy) assimilation
test and the splitting of esculin were used as additional
tests for the differentiation of lipid-dependent yeasts
[14,15].
At each follow-up, bacterial infections were evaluated by
cytological examination using sterile swabs for sampling.
The collected material was smeared on a clean glass slide,
heat-fixed and stained with May-Grunwald Giemsa for
microscopic examination. Bacterial infection was con-
firmed if more than 2 cells morphologically identifiable
as cocci were found in five microscopic fields at 40× mag-
nification [16].
The dog was topically treated with the spot-on formula-
tion containing 499.5 mg of metaflumizone and 499.5
mg of amitraz. The compound was administered on the
skin of the animal according to the manufacturer's
instructions. The dog was treated at two-week intervals on
days 0, +14, +28, +42, +56, +70 and +84. Cephalexin (30
mg/kilograms/12 h for 4 weeks) was also administered to
treat the concurrent pyoderma until the bacterial cytolog-
ical examination tested negative. The differences in mean
numbers of Demodex  spp. mites after treatment with
metaflumizone plus amitraz at 14 days intervals were sta-
tistically analysed using the T-student test. A value of P =
0.05 was considered statistically significant.
The results of parasitological examination from each skin
site at each observation time are reported in Additional
file 1. At day 0 each sample was positive for different
stages of Demodex canis (Additional file 1) with the high-
est parasitic load recorded on the thorax and thighs. The
number of adult mites statistically decreased at follow-up
with a reduction of approximately 42 and 94% at +14 and
+28 days p.t. respectively. Nymphs and larvae could no
longer be detected from day +28 p.t., while eggs were no
longer observed from day +42 p.t. At the same time, gen-
eral condition improved and skin lesions resolved, and
clinical signs of pruritus disappeared at +14 day p.t. (Fig-
ure 1). Lesions due to scratching rapidly resolved over the
whole body surface, as well as around the eyes, resulting
in hair growth and resolution of alopecic areas. At +70 day
p.t. the animal presented in good general condition,
including a weight gain of +7 kilos (Figure 2). No adverse
reactions to treatment were recorded at any of the follow-
ups.
The results of mycological examination from each skin
site at each observation time are reported in Table 1. Over-
all, 52 isolates were collected, identified biochemically as
M. pachydermatis and isolated from each anatomical site at
time +0 and +14 p.t. except for the periorbital area. M.
pachydermatis was retrieved throughout the entire observa-
tion time from the external ear canal with a significant
decrease (p < 0.05) in the population size (Table 1). The
results of cytological examination revealed the presence of
bacterial infection up to +14 day p.t.
The application of a metaflumizone and amitraz spot-on
formulation at 14 days intervals for 3 months was highly
effective for the treatment of generalized demodectic
mange and contributed to clinical recovery. Treatment
with metaflumizone and amitraz spot-on formulation
was shown to be easy to handle, safe and efficacious
against canine demodectic mange. Currently, amitraz
rinsing is the only treatment approved by the FDA for
canine demodicosis, although its use can be very labour-
intensive and may lead to toxic effects [6]. Previous stud-
ies evaluated the efficacy of amitraz rinse against juvenile-
and adult-onset generalized demodicosis, demonstratingParasites & Vectors 2009, 2:13 http://www.parasitesandvectors.com/content/2/1/13
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remission of the clinical signs after long-term amitraz
therapy in 65% of the animals, of which 9% maintained
the clinical remission with ongoing treatment [10]. Con-
versely, 25% of the animals did not respond to the ther-
apy [10]. Similar remission rates have been reported for
long-term, high-dose, daily therapy with ivermectin or
milbemycin oxime and moxidectin [10,17]. However,
treatment regimes with these macrocyclic lactones are
costly, intensive (daily treatment), long (usually 3
months), and may be associated with adverse events [6].
Interestingly, treatment by metaflumizone plus amitraz
spot-on was also effective in reducing the number of M.
pachydermatis yeasts in each sampling site at +28 days p.t.
Although M. pachydermatis cells could still be detected in
the external ear canal, the population size decreased sig-
nificantly from +28 days p.t. and at day +70, the yeast load
was considered normal (i.e. about 20 CFU) [4].
These findings suggest that the alterations in the cutane-
ous microenvironment and/or in host defence mecha-
nisms in canine skin may have influenced the mite
development, M. pachydermatis and bacterial overgrowth
thus leading to the appearance of skin lesions. However,
while the acaricidal and antibiotic treatment may account
for the reduction in mite number and presence of bacte-
rial lesions, the reduction of M. pachydermatis needs fur-
ther investigation. M. pachydermatis is an opportunistic
pathogen and the metaflumizone and amitraz spot-on
formulation, as well as antibiotic treatment, may have
reduced yeast population as an additional effect of the
acaricidal activity leading to the improvement of skin
lesions.
In conclusion, the results of the case report presented here
show that metaflumizone plus amitraz in a spot-on for-
mulation, associated with antibiotic therapy, was highly
effective for the treatment of generalized demodectic
mange and this could contribute to the control of also
these opportunistic infections. Nonetheless, the complex
interactions occurring among the host immune response
and the bacterial and yeast infections associated with
canine demodectic generalized mange, need to be
addressed in order to standardize effective and safe treat-
ment with reduced administration times.
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Patient at day +42, +56, +70 and +84 post treatment Figure 2
Patient at day +42, +56, +70 and +84 post treatment.
Table 1: Population size of Malassezia pachydermatis expressed as number of colony forming units (CFU) per swab from different 
anatomical regions and sampling time.
Sampling Sites 0 +14 +28 +42 +56 +70 +84
Inguinal area 78 68 neg neg neg neg neg
Interdigital area 120 80 neg neg neg neg neg
External Ear Canal 300 250 45 37 36 24 18
Perioral 32 16 neg neg neg neg neg
Periorbital neg neg neg neg neg neg neg
Means (standard deviation) 106 (117.6) 86.8 (99.6) 9 (20.1) 7.4 (16.5) 7.2 (16.5) 4.8 (10.7) 3.6 (8)Publish with BioMed Central    and   every 
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